Performance of Seven-Gene Panel Testing for Risk Stratification of Thyroid Nodules with Indeterminate Cytology Results
Open Access
- 30 May 2026
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (11) , 4990
Abstract
Risk stratification of thyroid nodules is mainly based on ultrasound examination and fine-needle aspiration (FNA) cytology findings. Molecular testing has increasingly been added to the workup to improve risk of malignancy (ROM) estimation. Here, we evaluated the diagnostic performance of alterations in seven genes, including point mutations in BRAF, HRAS, KRAS, and NRAS as well as RET/PTC1, RET/PTC3, and PAX8/PPARγ fusions in 849 FNA samples with cytopathologically indeterminate Bethesda categories (III, IV, and V). In 20.14% of samples, at least one gene alteration was detected, with NRAS mutations and the BRAF V600E variant occurring most frequently. For 636 of the thyroid nodules, surgical follow-up was available, with a malignancy rate of 22.64%. BRAF V600E mutations and RET/PTC1 fusions were associated with a ROM of 100%, RAS mutations with 13.64%, and PAX8/PPARγ fusions with 60.00%. Depending on the Bethesda category, the positive predictive value for malignancy of the seven-gene panel ranged between 18.18% (Bethesda III) and 91.07% (Bethesda V), while the negative predictive value ranged between 93.92% (Bethesda III) and 24.14% (Bethesda V). In conclusion, molecular testing with the seven-gene panel can improve ROM estimation in cytopathologically indeterminate thyroid nodules, but its clinical utility depends on the detected gene alteration.Keywords
This publication has 46 references indexed in Scilit:
- Revisionist history uncovers a simplified molecular‐based classification of differentiated thyroid cancerThe Journal of Pathology, 2025
- The Bethesda System for Reporting Thyroid Cytopathology2023
- RAS mutation and associated risk of malignancy in the thyroid gland: An FNA study with cytology‐histology correlationCancer Cytopathology, 2021
- Diagnostic and prognostic value of a 7-panel mutation testing in thyroid nodules with indeterminate cytology: the SWEETMAC studyEndocrine, 2020
- Evaluation of BRAF, RAS, RET/PTC, and PAX8/PPARg alterations in different Bethesda diagnostic categories: A multicentric prospective study on the validity of the 7‐gene panel test in 1172 thyroid FNAs deriving from different hospitals in South ItalyCancer Cytopathology, 2019
- Systematic Review and Meta-analysis of the Impact of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP) on Cytological Diagnosis and Thyroid Cancer PrevalenceEndocrine Pathology, 2019
- The Diagnosis and Management of Thyroid NodulesJAMA, 2018
- The Bethesda System for Reporting Thyroid Cytopathology2018
- Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid CarcinomaJAMA Oncology, 2016
- American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: Executive Summary of recommendationsJournal of Endocrinological Investigation, 2010